Serum Institute of India is the world’s largest vaccine manufacturer with over 1.5 billion doses produced and sold each year. The company is producing 5.000 doses of the covid-19 Covishield vaccine per minute. Fedegari in close collaboration with Serum and ACE Technologies provided an advanced solution for a fully robotized plant without human intervention, increasing the efficiency of processing and transferring of sterile closures.
Serum dispatches around 11 million vaccine doses in a day and is proudly working on other three covid-19 vaccine candidates developed in partnership with AstraZeneca, Novavax and Codagenix. This means that Serum is ready to manufacture more than 1.5 billion doses of the covid-19 vaccine.
Fedegari Group has recently concluded the installation of a state-of-the-art robotized system for processing pharmaceutical closures at the biotech manufacturing laboratories of Serum Institute of India that are helping to increase the vaccine production capacity of the company.
The product that we developed for the Serum Institute provides an advanced solution for a fully robotized plant, with the aim of increasing the efficiency of processing and transferring of sterile closures ready-to-use. The system uses a robotic arm that, by connecting to the filling line, allows the aseptic transfer of washed and sterilized closures, neutralizing any risk of external contamination. By doing this, Fedegari reduced 50% of steps in the workflow and optimized the manufacturing process with significant time, energy and cost savings.
Fedegari‘s final solution created a cleaner and safer environment, increased Serum’s production capacity and allowed to save costs on maintenance while having fewer machines involved in sterile processing.
If your vaccine production capabilities need some upgrades and optimization, do not hesitate to contact us.
